Erratum: Current and emerging biomarkers in metastatic colorectal cancer

Erratum


Erratum: Current and emerging biomarkers in metastatic colorectal cancer


M.K.C. Lee, MBChB, J.M. Loree, MD


doi: http://dx.doi.org/10.3747/co.26.6145

Original Citation

Curr Oncol 2019;26:S7–15. (doi: https://doi.org/10.3747/co.26.5719)

Description of the Error and Correction

In the initially published manuscript, the article stated (about the beacon clinical trial) that “Interestingly, the triplet did not appear more active than the combination of encorafenib and binimetinib (mos: 9.0 months vs. 8.4 months; hr: 0.79; 95% ci: 0.59 to 1.06).”

That was an error, because the doublet arm in beacon used encorafenib and cetuximab. The sentence should read “Interestingly, the triplet did not appear more active than the combination of encorafenib and cetuximab (mos: 9.0 months vs. 8.4 months; hr: 0.79; 95% ci: 0.59 to 1.06).”


(Return to Top)



Current Oncology, VOLUME 26, NUMBER 6, December 2019








Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)